chevron_leftBack
As of 9 June 2026, Taho Pharmaceuticals Ltd. has a market cap of $196.21M USD, ranking #21174 globally and #974 in Taiwan.
It ranks #1896 in the Healthcare sector, and #689 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$196.21MUSD
6.19B TWD
Enterprise Value
$183.94MUSD
5.81B TWD
Revenue (TTM)
$246.48KUSD
7.78M TWD
EBITDA (TTM)
-$5.34MUSD
-168.68M TWD
Net Income (TTM)
-$5.26MUSD
-165.97M TWD
PS Ratio
796.1
PB Ratio
13.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Shiren S. Lee
open_in_new
Employees
27
Founded
2010
Website
tahopharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | 7.1% | -11% | -15% | -21% | 98% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
6467
泰合生技藥品股份有限公司
ISIN: TW0006467004
Shares Out.:
Shares Outstanding:
52.371M1
Shares Float:
15.636M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
120.50 TWD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Taho Pharmaceuticals Ltd.
Taho Pharmaceuticals Ltd., a pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan. Its pipeline includes TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting; and TAH3311 Apixaban oral film and TAH3341 Apixaban oral extend release films for patients with Dysphagia. The company also develops TAH2211 Buprenorphine/Naloxone sublingual film and TAH2231 Naloxone Buccal film for Opioid overdose; TAH9922 Atomoxetine oral liquid and TAH9901 Methylphenidate patch for ADHD treatment. Taho Pharmaceuticals Ltd. was founded in 2010 and is based in Taipei, Taiwan.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TWSE: 6446
|
$7.77B
4K%
245.34B TWD
|
48.6
|
|
TWSE: 1795
|
$1.84B
836%
57.95B TWD
|
12.2
|
|
TPEX: 4123
|
$922.51M
370%
29.11B TWD
|
3.4
|
|
TPEX: 6535
|
$806.64M
311%
25.46B TWD
|
-
|
|
TPEX: 4743
|
$786.54M
301%
24.82B TWD
|
-
|
|
TPEX: 4105
|
$582.23M
197%
18.38B TWD
|
11.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
388K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
279K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
184K%
|
97.4
|
|
SIX: RO
|
$322.98B
165K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.68B
147K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$275.9B
141K%
218.9B CHF
|
20.5
|
chevron_leftBack